While advances in GLP-1 and GIP agonists are promising, long-term outcomes remain uncertain, and current data continue to position bariatric and metabolic surgery as the gold standard for treating severe obesity with complex multi-morbidity. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.